A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
暂无分享,去创建一个
F. Chen | M. Millward | J. Creaney | A. Nowak | C. Read | K. Murray | A. Chakera | Y. Gary Lee | S. Muruganandan | M. Attia | W. Chin | S. Arunachalam | J. Spiro | Wei-Sen Lam | W. Lam